As the leading cause of cancer-related mortality, lung cancer is a worldwide health issue
that is overwhelmingly caused by smoking. However, a substantial minority (~ 25%) of …

Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)
represent the standard of care for patients with metastatic non-small-cell lung cancer …

Background: Lung cancer is the leading cause of cancer mortality, being responsible for
more than 1.6 million deaths each year worldwide and non-small-cell lung cancer (NSCLC) …

In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor
(EGFR) mutations and the parallel development of EGFR tyrosine kinase inhibitors (TKIs) …

Simple Summary Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth
factor receptor (EGFR) in advanced mutant non-small cell lung cancer (NSCLC) constitutes …

Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors
(TKIs) is highly effective in terms of tumor response rate, survival, and quality of life …

Three generations of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKIs) have been developed for treating advanced/metastatic non-small cell lung cancer …

Opinion statement Patients whose tumors harbor somatic-activating mutations within the
epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of …

Non-small-cell lung cancer (NSCLC) constitutes 85% of patients diagnosed with lung
cancer. In metastatic cases, its treatment classically consists of systemic cytotoxic …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) monotherapy has
been regarded as the standard first-line treatment of advanced non–small cell lung cancer …